These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

783 related articles for article (PubMed ID: 31048320)

  • 21. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.
    Anderson MA; Deng J; Seymour JF; Tam C; Kim SY; Fein J; Yu L; Brown JR; Westerman D; Si EG; Majewski IJ; Segal D; Heitner Enschede SL; Huang DC; Davids MS; Letai A; Roberts AW
    Blood; 2016 Jun; 127(25):3215-24. PubMed ID: 27069256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal
    Prukova D; Andera L; Nahacka Z; Karolova J; Svaton M; Klanova M; Havranek O; Soukup J; Svobodova K; Zemanova Z; Tuskova D; Pokorna E; Helman K; Forsterova K; Pacheco-Blanco M; Vockova P; Berkova A; Fronkova E; Trneny M; Klener P
    Clin Cancer Res; 2019 Jul; 25(14):4455-4465. PubMed ID: 31004002
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells.
    Zhao J; Niu X; Li X; Edwards H; Wang G; Wang Y; Taub JW; Lin H; Ge Y
    Oncotarget; 2016 Jun; 7(23):34785-99. PubMed ID: 27166183
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Venetoclax and pegcrisantaspase for complex karyotype acute myeloid leukemia.
    Emadi A; Kapadia B; Bollino D; Bhandary B; Baer MR; Niyongere S; Strovel ET; Kaizer H; Chang E; Choi EY; Ma X; Tighe KM; Carter-Cooper B; Moses BS; Civin CI; Mahurkar A; Shetty AC; Gartenhaus RB; Kamangar F; Lapidus RG
    Leukemia; 2021 Jul; 35(7):1907-1924. PubMed ID: 33199836
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Embelin potentiates venetoclax-induced apoptosis in acute myeloid leukemia cells.
    Reis-Silva CSM; Branco PC; Lima K; Silva FL; Moreno PRH; Guallar V; Costa-Lotufo LV; Machado-Neto JA
    Toxicol In Vitro; 2021 Oct; 76():105207. PubMed ID: 34216723
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cotargeting of Bcl-2 and Mcl-1 shows promising antileukemic activity against AML cells including those with acquired cytarabine resistance.
    Liu F; Zhao Q; Su Y; Lv J; Gai Y; Liu S; Lin H; Wang Y; Wang G
    Exp Hematol; 2022 Jan; 105():39-49. PubMed ID: 34767916
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combining triptolide with ABT-199 is effective against acute myeloid leukemia through reciprocal regulation of Bcl-2 family proteins and activation of the intrinsic apoptotic pathway.
    Shi YF; Liu L; He LL; Ye J; Lin ZJ; Yuan DL; Deng MM; Fang ZH; Carter BZ; Xu B
    Cell Death Dis; 2020 Jul; 11(7):555. PubMed ID: 32699295
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NL101 synergizes with the BCL-2 inhibitor venetoclax through PI3K-dependent suppression of c-Myc in acute myeloid leukaemia.
    Lu Y; Jiang X; Li Y; Li F; Zhao M; Lin Y; Jin L; Zhuang H; Li S; Ye P; Pei R; Jin J; Jiang L
    J Transl Med; 2024 Sep; 22(1):867. PubMed ID: 39334157
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting Apoptosis in Acute Myeloid Leukemia: Current Status and Future Directions of BCL-2 Inhibition with Venetoclax and Beyond.
    Choi JH; Bogenberger JM; Tibes R
    Target Oncol; 2020 Apr; 15(2):147-162. PubMed ID: 32319019
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo.
    Liu F; Knight T; Su Y; Edwards H; Wang G; Wang Y; Taub JW; Lin H; Sun L; Ge Y
    Target Oncol; 2019 Jun; 14(3):351-364. PubMed ID: 31115744
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia.
    Zhang L; Cai T; Lin X; Huang X; Bui MH; Plotnik JP; Bellin RJ; Faivre EJ; Kuruvilla VM; Lam LT; Lu X; Zha Z; Feng W; Hessler P; Uziel T; Zhang Q; Cavazos A; Han L; Ferguson DC; Mehta G; Shanmugavelandy SS; Magoc TJ; Rowe J; Goodwin NC; Dorritie KA; Boyiadzis M; Albert DH; McDaniel KF; Kati WM; Konopleva M; Shen Y
    Mol Cancer Ther; 2021 Oct; 20(10):1809-1819. PubMed ID: 34253595
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synergistic AML Cell Death Induction by Marine Cytotoxin (+)-1(
    Florean C; Kim KR; Schnekenburger M; Kim HJ; Moriou C; Debitus C; Dicato M; Al-Mourabit A; Han BW; Diederich M
    Mar Drugs; 2018 Dec; 16(12):. PubMed ID: 30572618
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined Application of Pan-AKT Inhibitor MK-2206 and BCL-2 Antagonist Venetoclax in B-Cell Precursor Acute Lymphoblastic Leukemia.
    Richter A; Fischer E; Holz C; Schulze J; Lange S; Sekora A; Knuebel G; Henze L; Roolf C; Murua Escobar H; Junghanss C
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33803402
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Elevated expression of S100A8 and S100A9 correlates with resistance to the BCL-2 inhibitor venetoclax in AML.
    Karjalainen R; Liu M; Kumar A; He L; Malani D; Parsons A; Kontro M; Kallioniemi O; Porkka K; Heckman CA
    Leukemia; 2019 Oct; 33(10):2548-2553. PubMed ID: 31175323
    [No Abstract]   [Full Text] [Related]  

  • 35. Systematic Dissection of the Metabolic-Apoptotic Interface in AML Reveals Heme Biosynthesis to Be a Regulator of Drug Sensitivity.
    Lin KH; Xie A; Rutter JC; Ahn YR; Lloyd-Cowden JM; Nichols AG; Soderquist RS; Koves TR; Muoio DM; MacIver NJ; Lamba JK; Pardee TS; McCall CM; Rizzieri DA; Wood KC
    Cell Metab; 2019 May; 29(5):1217-1231.e7. PubMed ID: 30773463
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of a Covalent Inhibitor That Overcame Resistance to Venetoclax in AML Cells Overexpressing BFL-1.
    Lou J; Zhou Q; Lyu X; Cen X; Liu C; Yan Z; Li Y; Tang H; Liu Q; Ding J; Lu Y; Huang H; Xie H; Zhao Y
    J Med Chem; 2024 Jul; 67(13):10795-10830. PubMed ID: 38913996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia.
    Eide CA; Kurtz SE; Kaempf A; Long N; Agarwal A; Tognon CE; Mori M; Druker BJ; Chang BH; Danilov AV; Tyner JW
    Leukemia; 2020 Sep; 34(9):2342-2353. PubMed ID: 32094466
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potential mechanisms of resistance to venetoclax and strategies to circumvent it.
    Tahir SK; Smith ML; Hessler P; Rapp LR; Idler KB; Park CH; Leverson JD; Lam LT
    BMC Cancer; 2017 Jun; 17(1):399. PubMed ID: 28578655
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MCL-1 or BCL-xL-dependent resistance to the BCL-2 antagonist (ABT-199) can be overcome by specific inhibitor as single agents and in combination with ABT-199 in acute myeloid leukemia cells.
    Wang Q; Wan J; Zhang W; Hao S
    Leuk Lymphoma; 2019 Sep; 60(9):2170-2180. PubMed ID: 30626241
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Venetoclax triggers sublethal apoptotic signaling in venetoclax-resistant acute myeloid leukemia cells and induces vulnerability to PARP inhibition and azacitidine.
    Tambe M; Unterberger S; Kriegbaum MC; Vänttinen I; Olgac EJ; Vähä-Koskela M; Kontro M; Wennerberg K; Heckman CA
    Cell Death Dis; 2024 Oct; 15(10):750. PubMed ID: 39414773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.